TeleTicino, Ticinonews 2e edizione 24.6.2021 Interview with Dr. Daniela Marino and reportage on CUTISS’s unveiling of the denovoCast, the world’s first automated machine to produce customized skin tissue grafts for adults and children with severe skin injuries, such as deep burns. Watch the interview and reportage starting at minute 12:43. Newsroom LInk to video
TeleTicino: “Skin-Machine from Switzerland” Read More »
CUTISS develops world’s first machine to produce personalized human skin tissue therapy A world-first innovation in tissue engineering and regenerative medicine that can lead to life-saving and life-changing medical treatments for millions of people with severe skin injuries Over 11 million people annually suffer from severe burns needing surgery Significant milestone in the company’s automation
CUTISS develops world’s first machine to produce personalized human tissue Read More »
The latest edition of Burns Open, the peer reviewed international journal, has published the case report of the first ever compassionate use of denovoSkin in a child patient.
The patient had experienced a 95% total body surface area (TBSA) deep flame burn, and the use of a bio-engineered dermo-epidermal skin graft was therefore justified and permitted. A total of 1,626 cm2 of denovoSkin was transplanted onto the patient (approximately 20% TBSA).
This first large-scale application of denovoSkin reported:
– Ease of handling and application
– Excellent engraftment rates (80 – 90%) over dermal substitutes as well as over allodermal remnants
– Soft and solid, close to natural skin coverage, after a maturation process
As such, the reported case has delivered the clinical proof of principle that denovoSkin has the potential to help substantially in severe and acute burns.
It must be noted that, despite the promising skin grafting and healing process, the patient sadly died from multiple organ failure unrelated to the grafts. We believe that in the future, if denovoSkin can be applied sooner and in greater quantities in such disastrous cases, then it could lead to life-saving outcomes.
As the authors in the report conclude, the prospect of scaling up denovoSkin to provide more rapid response and treatment for major burns would be “a paradigm shift in the care of such patients”.
The full report case can be read online, see link below.
denovoSkin has Orphan Drug Designation for the treatment of partial and full thickness burn wounds by Swissmedic, EMA, and FDA. It is currently in Phase II clinical trials comparing denovoSkin to conventional split-thickness skin grafts.
First ever compassionate use of denovoSkin delivers proof of principle Read More »
CUTISS AG is present with a booth at the EBA 2019 in Helsinki. Further information about the congress, also for the upcoming events of the EBA can be found under “Learn more”
Swiss researchers want to develop the first-ever automated machine to bioengineer personalised skin grafts for therapy. The denovoCast project, a collaboration between life science start-up Cutiss AG and CSEM, has been awarded a grant of more than CHF 800’000 by Innosuisse.
CSEM article on Innosuisse Grant Read More »
Switzerland is perfect for Startups, but… Switzerland boasts some of the best skills in the world, according to Daniela Marino. The Cutiss CEO says Switzerland is also the “perfect place” to be an entrepreneur. So what’s the catch? When it comes to money, Swiss investors aren’t as willing to take risks as their American counterparts.
Interview mit Daniela Marino auf CNN Money Switzerland.
Interview with Daniela Marino on CNN Money Switzerland Read More »
CUTISS reaches milestone: publication of Phase I of the Clinical Studies of denovoSkin!
CUTISS reaches milestone in Clinical Studies Read More »
The denovoFix transport box was developed by Astrid Welti as a Bachelor Thesis in cooperation with the Zürcher Hochschule der Künste (ZHdK).
denovoFix – transport box for skin biopsy Read More »
“The B round will need to provide 30-40 million CHF to support the market access.”
by Patrick Gunti
Moneycab.com: Ms. Marino, Cutiss has developed a revolutionary method to produce human skin in the lab. How did that happen?
In 2001 the Tissue Biology Reseach Unit, a research lab of the Department of Surgery of the University Children’s hospital in Zurich started working on skin bio-engineering to solve an unmet clinical need mostly connected to burns. Unfortunately, standard of care to treat large, deep burns is scarce and ineffective leading very often to highly debilitating, disfiguring scarring. Via personalized skin tissue bio-engineering one could permanently treat large wound surfaces and minimize the scarring.
Interview with Daniela Marino on Moneycab.com Read More »
Article in French only.
Start-up suisse créée en 2017 et spécialisée dans la biotechnologie, CUTISS AG est une jeune entreprise adossée à l’Université de Zürich. Son application ? La peau ! Spécialisée dans la reconstitution de peau sur-mesure, Cutiss travaille main dans la main avec des hôpitaux européens, Suisses, Hollandais et Anglais, et travaille déjà à son futur : démocratiser la fabrication de peau pour les grands blessés et pour toutes les autres personnes ayant besoin d’une greffe de peau.
Forbes article about CUTISS “La peau sur mesure” Read More »
CUTISS AG
CUTISS HAUS
Grabenstrasse 11
8952 Schlieren, Switzerland
info@cutiss.swiss
Tel. +41 44 244 36 60
© Cutiss AG. All rights reserved.
Would you like to contact us as a journalist?
